S&P TSX Capped Composite...

US Dollar vs CAD

Level up your trading with our powerful tools and real-time insights all in one place.

Get Started

TEVA Teva Pharmaceutical Industries Ltd

17.73

0.00 (0.00%)

Feb 02 2025 - Closed

Delayed by 15 minutes

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Article too big to display. Click here to view on the SEC website

Teva Pharmaceutical Indu... (NYSE:TEVA)
Historical Stock Chart
From Jan 2025 to Feb 2025

Click Here for more Teva Pharmaceutical Indu... Charts.

Teva Pharmaceutical Indu... (NYSE:TEVA)
Historical Stock Chart
From Feb 2024 to Feb 2025

Click Here for more Teva Pharmaceutical Indu... Charts.

Teva Pharmaceutical Industries Ltd News

Teva Delivers Second Consecutive Year of Growth; Announces Strong Financial Results in Fourth Quarter and Full Year 2024, Led by Generics Performance and Innovative Portfolio Growth
Wednesday 29 January 2025 (5 days ago) • GlobeNewswire Inc.

Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Applications for AVT05, a Proposed Biosimilar to Simponi® and Simponi Aria® (golimumab)
Monday 27 January 2025 (7 days ago) • GlobeNewswire Inc.

Teva Announces Collaboration to Commercialize Formycon’s Biosimilar Candidate to Eylea® (aflibercept) in major parts of Europe and in Israel
Monday 13 January 2025 (3 weeks ago) • GlobeNewswire Inc.

Samsung Bioepis and Teva Enter into a Strategic Partnership for Commercialization of EPYSQLI® (eculizumab-aagh) in the United States
Friday 10 January 2025 (3 weeks ago) • GlobeNewswire Inc.

Form 4 - Statement of changes in beneficial ownership of securities
Thursday 26 December 2024 (1 month ago) • Edgar (US Regulatory)

Teva to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Monday 23 December 2024 (1 month ago) • GlobeNewswire Inc.

Teva to Host Conference Call to Discuss Fourth Quarter and Full Year 2024 Financial Results and 2025 Financial Guidance at 8 a.m. ET on January 29, 2025
Friday 20 December 2024 (1 month ago) • GlobeNewswire Inc.

Teva and Sanofi Announce Duvakitug (Anti-TL1A) Positive Phase 2b Results Demonstrating Best-in-Class Potential in Ulcerative Colitis and Crohn’s Disease
Tuesday 17 December 2024 (2 months ago) • GlobeNewswire Inc.

Teva Announces New Patient Access Program with Direct Relief to Provide Access to Inhalers for Uninsured Patients
Wednesday 11 December 2024 (2 months ago) • GlobeNewswire Inc.

Teva Announces Agreement to Divest Teva-Takeda, its Business Venture in Japan
Thursday 5 December 2024 (2 months ago) • GlobeNewswire Inc.

Teva Presents Positive Efficacy and Safety Data of AJOVY® (fremanezumab) for the Prevention of Episodic Migraine in Children and Adolescents from Phase 3 SPACE Trial
Wednesday 4 December 2024 (2 months ago) • GlobeNewswire Inc.

Teva to Present at the 7th Annual Evercore ISI HealthCONx Conference
Monday 25 November 2024 (2 months ago) • GlobeNewswire Inc.

More Teva Pharmaceutical Industries Ltd News Articles

Liquidmetal Technologies (QB)

RespireRx Pharmaceuticals (CE)

Moon Equity (PK)

Bioelectronics (PK)

Lightwave Logic

Northwest Biotherapeutics (QB)

Anavex Life Sciences

Valiant Eagle (PK)

Intergrated Cannabis Sol... (PK)

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions